Eloralintide vs cagrilintide: compare these two investigational amylin receptor agonists by developer, dosing, trial results, safety profile, and FDA status.
Eloralintide and cagrilintide are both investigational amylin receptor agonists — once-weekly injectable peptides that mimic the hormone amylin to reduce appetite and slow stomach emptying. The biggest difference today is development stage: cagrilintide (Novo Nordisk) is the amylin component of CagriSema and has completed phase 3 testing, while eloralintide (Eli Lilly) is an earlier-stage amylin analog with phase 2 obesity data. Neither drug is FDA-approved for human use in the United States.
What Is Eloralintide?
Eloralintide is an amylin receptor agonist peptide being developed by Eli Lilly for obesity and related metabolic conditions. In trials it is given as a once-weekly subcutaneous injection, the same route and schedule used by most modern weight-management peptides.
- Developer: Eli Lilly and Company.
- Drug class: Amylin receptor agonist.
- Dosing: Once-weekly subcutaneous injection in clinical studies.
- Status: Phase 2 completed in obesity; phase 3 trials ongoing.
Lilly has reported average weight reductions approaching 20% at 48 weeks at the highest dose tested in a phase 2 trial of adults with obesity. The side effect profile was dominated by gastrointestinal symptoms, which is consistent with the amylin and incretin drug classes. Lilly is also exploring eloralintide in combination with other pipeline assets.
What Is Cagrilintide?
Cagrilintide is a long-acting, acylated analog of human amylin developed by Novo Nordisk. Its fatty-acid modification extends its half-life so it can be dosed once weekly, and it is studied both as a standalone peptide and in combination with semaglutide under the name CagriSema.
In the phase 3 REDEFINE 1 trial, CagriSema produced roughly 20% average weight loss at 68 weeks, while cagrilintide 2.4 mg alone produced about 12% and semaglutide 2.4 mg alone about 15%. Novo Nordisk has submitted CagriSema for regulatory review, with a US decision expected in 2026. Cagrilintide by itself is not approved as a standalone product.
Eloralintide vs Cagrilintide at a Glance
| Feature | Eloralintide | Cagrilintide |
|---|---|---|
| Developer | Eli Lilly | Novo Nordisk |
| Drug class | Amylin receptor agonist | Acylated human amylin analog |
| Route | Subcutaneous injection | Subcutaneous injection |
| Dosing frequency | Once weekly (trials) | Once weekly |
| Development stage | Phase 3 ongoing | Phase 3 complete; filed for approval as CagriSema |
| Signature combination | Other Lilly pipeline assets | Semaglutide (CagriSema) |
| FDA status | Not approved | Not approved |
How Amylin Agonists Compare With GLP-1 Drugs
Amylin receptor agonists act on a different receptor system than GLP-1 medicines such as semaglutide. Many readers arrive at this topic after researching cagrilintide vs tirzepatide and wondering whether amylin is simply a weaker incretin — it is not. Amylin and GLP-1 receptors are distinct, which is exactly why combinations like CagriSema are being tested.
Cross-class comparisons such as cagrilintide vs retatrutide involve even more moving parts, because retatrutide targets three receptors (GLP-1, GIP, and glucagon) rather than one. No head-to-head trial has directly compared eloralintide, cagrilintide, tirzepatide, or retatrutide, so any ranking you see online is based on separate studies with different populations and durations.
Side Effects and Safety Considerations
Both compounds belong to the same broad family of appetite-suppressing peptides, and their reported side effects overlap.
- Nausea, vomiting, diarrhea, and constipation are the most common complaints.
- Injection-site reactions such as redness or mild pain can occur.
- Reduced appetite and fatigue are frequently reported during dose escalation.
- Rare but serious events seen across this drug class include gallbladder disease and pancreatitis.
- Low blood sugar is a risk when these drugs are combined with insulin or sulfonylureas.
Because eloralintide and cagrilintide are investigational, they should only be used inside supervised clinical trials. Anyone considering an amylin-based therapy should discuss risks, contraindications, and pregnancy precautions with a licensed healthcare professional.
What Researchers Still Need to Learn
Several open questions will shape how these two drugs are eventually used.
- No study has compared eloralintide and cagrilintide directly, so relative potency remains unknown.
- It is unclear how much weight loss persists after treatment stops.
- Effects on lean muscle mass during rapid weight loss are still being measured.
- Cardiovascular and kidney outcome trials are needed before long-term benefits can be claimed.
Until those data exist, comparing drugs across trials is a rough exercise at best.
Other Peptides People Compare
Metabolic and peptide research stretches well beyond amylin. Searchers often weigh aod 9604 vs mots-c when reading about fat-loss peptides, and sermorelin vs aod 9604 when comparing growth-hormone pathways. Those compounds belong to entirely different categories than eloralintide and cagrilintide, and none of them are FDA-approved for weight loss.
The practical takeaway is simple: eloralintide and cagrilintide are both amylin receptor agonists, cagrilintide is further along in development, and neither is legally available as a prescription medicine today.
Frequently Asked Questions
Is eloralintide FDA approved?
No. Eloralintide is an investigational amylin receptor agonist from Eli Lilly and has not been approved by the FDA for any indication. It has completed phase 2 testing in obesity, and phase 3 trials were ongoing as of 2025.
What is the main difference between eloralintide and cagrilintide?
Both are once-weekly amylin receptor agonists, but cagrilintide is developed by Novo Nordisk and is much further along, having completed phase 3 testing as part of CagriSema. Eloralintide is Eli Lilly's amylin analog and remains in phase 3 development as a standalone candidate.
Can you buy eloralintide or cagrilintide online?
No. Neither drug is FDA-approved, so there is no legal prescription supply in the United States. Products sold online as "research-grade" eloralintide or cagrilintide are not intended for human use, are often unverified in purity, and carry real safety risks.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.